Glenmark Pharma has received final USFDA approval for Sevelamer Hydrochloride tablets to market the same in US markets. The product is prescribe for controlling serum phosphorus in patients with chronic kidney disease on dialysis.
It will be manufactured in the strengths of 400 mg and 800 mg. The drug is a generic version of Genzyme Corporation’s Renagel tablets. According to market estimates, Renagel tablets has a market potential of approximately USD 102.1 million, for a period of 12 months.
Company Profile : Glenmark Pharma Ltd
Leave a Reply